BR112013027089A2 - composto, composição farmacêutica e método para usar um composto - Google Patents

composto, composição farmacêutica e método para usar um composto

Info

Publication number
BR112013027089A2
BR112013027089A2 BR112013027089A BR112013027089A BR112013027089A2 BR 112013027089 A2 BR112013027089 A2 BR 112013027089A2 BR 112013027089 A BR112013027089 A BR 112013027089A BR 112013027089 A BR112013027089 A BR 112013027089A BR 112013027089 A2 BR112013027089 A2 BR 112013027089A2
Authority
BR
Brazil
Prior art keywords
compound
pharmaceutical composition
diazonamide
antimitotic
cancer
Prior art date
Application number
BR112013027089A
Other languages
English (en)
Inventor
Caldwell Charles
Wang Lai
Zhou Ming
Wei Qi
Harran Susan
Xu Xiaoming
Original Assignee
Joyant Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Joyant Pharmaceuticals Inc filed Critical Joyant Pharmaceuticals Inc
Publication of BR112013027089A2 publication Critical patent/BR112013027089A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Photosensitive Polymer And Photoresist Processing (AREA)
  • Thermistors And Varistors (AREA)
  • Non-Silver Salt Photosensitive Materials And Non-Silver Salt Photography (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

composto, composição farmacêutica e método para usar um composto trata-se de análogos de diazonamida que têm atividade antimitótica, úteis para o tratamento de câncer e outros distúrbios proliferadores, e composições farmacêuticas relacionadas.
BR112013027089A 2011-04-22 2012-04-15 composto, composição farmacêutica e método para usar um composto BR112013027089A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161478059P 2011-04-22 2011-04-22
PCT/US2012/033715 WO2012145255A2 (en) 2011-04-22 2012-04-15 Diazonamide analogs

Publications (1)

Publication Number Publication Date
BR112013027089A2 true BR112013027089A2 (pt) 2017-10-31

Family

ID=47021791

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013027089A BR112013027089A2 (pt) 2011-04-22 2012-04-15 composto, composição farmacêutica e método para usar um composto

Country Status (22)

Country Link
US (2) US8592469B2 (pt)
EP (1) EP2699580B1 (pt)
JP (1) JP6045083B2 (pt)
KR (1) KR101839642B1 (pt)
CN (1) CN103582645B (pt)
AU (1) AU2012245702B2 (pt)
BR (1) BR112013027089A2 (pt)
CA (1) CA2833956C (pt)
DK (1) DK2699580T3 (pt)
ES (1) ES2652444T3 (pt)
HR (1) HRP20171930T1 (pt)
HU (1) HUE037730T2 (pt)
IL (1) IL228985A (pt)
LT (1) LT2699580T (pt)
MX (1) MX351961B (pt)
NO (1) NO2636579T3 (pt)
PL (1) PL2699580T3 (pt)
PT (1) PT2699580T (pt)
RU (1) RU2608308C2 (pt)
SG (1) SG194223A1 (pt)
SI (1) SI2699580T1 (pt)
WO (1) WO2012145255A2 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021130515A1 (en) * 2019-12-23 2021-07-01 Latvian Institute Of Organic Synthesis Structurally simplified diazonamide analogs as antimitotic agents

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4261989A (en) 1979-02-19 1981-04-14 Kaken Chemical Co. Ltd. Geldanamycin derivatives and antitumor drug
US5387584A (en) 1993-04-07 1995-02-07 Pfizer Inc. Bicyclic ansamycins
US5932566A (en) 1994-06-16 1999-08-03 Pfizer Inc. Ansamycin derivatives as antioncogene and anticancer agents
US5624677A (en) 1995-06-13 1997-04-29 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
CA2411008C (en) 2000-06-07 2006-04-11 Lilly Icos Llc Derivatives of 2,3,6,7,12,12a-hexahydropyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione
US7439359B2 (en) 2000-11-02 2008-10-21 Sloan-Kettering Institute For Cancer Research Small molecule compositions for binding to hsp90
US7517895B2 (en) 2001-08-24 2009-04-14 Board Of Regents, The University Of Texas System Synthetic diazonamides
US7022720B2 (en) 2001-08-24 2006-04-04 Board Of Regents, The University Of Texas System Synthetic diazonamides as novel anti-mitotic agents
US7138402B2 (en) 2003-09-18 2006-11-21 Conforma Therapeutics Corporation Pyrrolopyrimidines and related analogs as HSP90-inhibitors
EA013692B1 (ru) * 2005-10-31 2010-06-30 Борд Оф Риджентс, Дзе Юниверсити Оф Техас Систем Аналог диазонамида а
EP2068904B1 (en) * 2007-06-07 2012-12-05 Joyant Pharmaceuticals, Inc. Methods for preparing diazonamides
EP2268146B1 (en) * 2008-04-29 2015-08-26 Joyant Pharmaceuticals, Inc. Indoline anti-cancer agents
US8153619B2 (en) * 2008-05-22 2012-04-10 Joyant Pharmaceuticals, Inc. Diazonamide analogs

Also Published As

Publication number Publication date
ES2652444T3 (es) 2018-02-02
IL228985A (en) 2016-08-31
US20140100193A1 (en) 2014-04-10
WO2012145255A2 (en) 2012-10-26
AU2012245702B2 (en) 2016-09-29
PL2699580T3 (pl) 2018-03-30
EP2699580B1 (en) 2017-09-27
SG194223A1 (en) 2013-11-29
MX2013012283A (es) 2014-07-09
DK2699580T3 (en) 2018-01-08
CA2833956C (en) 2020-05-12
KR101839642B1 (ko) 2018-03-16
LT2699580T (lt) 2018-01-10
PT2699580T (pt) 2018-01-04
US20120270841A1 (en) 2012-10-25
US8846734B2 (en) 2014-09-30
JP6045083B2 (ja) 2016-12-14
US8592469B2 (en) 2013-11-26
HUE037730T2 (hu) 2018-09-28
EP2699580A2 (en) 2014-02-26
AU2012245702A1 (en) 2013-11-07
EP2699580A4 (en) 2014-12-31
SI2699580T1 (en) 2018-04-30
IL228985A0 (en) 2013-12-31
MX351961B (es) 2017-10-17
RU2013148153A (ru) 2015-05-27
WO2012145255A3 (en) 2012-12-27
HRP20171930T1 (hr) 2018-02-09
CN103582645B (zh) 2016-02-24
RU2608308C2 (ru) 2017-01-17
NO2636579T3 (pt) 2018-07-21
JP2014512384A (ja) 2014-05-22
CA2833956A1 (en) 2012-10-26
KR20140053004A (ko) 2014-05-07
NZ616926A (en) 2015-09-25
CN103582645A (zh) 2014-02-12

Similar Documents

Publication Publication Date Title
SV2018005709A (es) 3-azabiciclo[3.1.0]hexanos sustituidos como inhibidores de cetohexoquinasa
CL2015002394A1 (es) Inhibidores de histona desmetilasas
CL2012003415A1 (es) Compuestos derivados de 2-oxo-piperidina y 1,1-dioxido-tiazina, inhibidores de mdm2; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer .
CL2014000746A1 (es) Compuestos derivados de 3-pirimidin-4-il-oxazolidin-2-ona y sus sales, como inhibidores de las proteinas idh mutantes; composicion farmaceutica que los comprende, utiles para el tratamiento de trastornos de la proliferacion celular tal como el cancer.
ECSP12012318A (es) Inhibidores de pirazolil quinazolina cinasa
SV2009003307A (es) Quinazolinas para la inhibicion de pdk1
GT201400111A (es) Triazolopiridinas sustituidas
BR112013007604A2 (pt) “composto, composição, método para controlar um nematoide parasitário e semente tratada”
EA201492223A1 (ru) Новые диазаспироциклоалканы и азаспироциклоалканы
CL2014000543A1 (es) Compuestos derivados de imidazopiridazinas sustituidas con amino, inhibidores de la quinasa ,mknk2; metodo de preparacion; compuestos intermediarios y su uso; composicion farmaceutica; combinacion farmaceutica; y su uso para el tratamiento del cancer.
BR112016028476A8 (pt) compostos, composição, uso de um composto e método para o combate dos fungos nocivos
BR112013031493A2 (pt) composto, composição farmacêutica, uso de um composto, combinação de um composto, dispositivo e processo de preparação de um composto.
NI201400042A (es) 2 - tiopirimidinonas
CR20120008A (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
BR112013006567A2 (pt) métodos e composições para tratamento de câncer de pulmão
BR112013016241A2 (pt) composto, e, método para fabricar um composto
CL2015000976A1 (es) Compuestos de 2-fenil-5-heterociclil-tetrahidro-2h-piran-3-amina para uso en el tratamiento de diabetes y sus trastornos asociados.
BR112017002852A2 (pt) compostos de azetidiniloxifenilpirrolidina
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.
CL2016000038A1 (es) Piraxolo-piridinaminas sustituidas
BR112015002493A2 (pt) composto , composição farmacêutica , método para o tratamento do câncer , processo para a preparação de uma composição farmacêutica , conjunto , utilização de um composto e invenção.
EP4023243A3 (en) Compositions and methods for treating celiac sprue disease
BR112018068027A2 (pt) método para tratar câncer em um paciente e composição farmacêutica
MX2013014488A (es) Metodos y composiciones para tratar el cancer cerebral.
BR112016018418A2 (pt) Composto, uso do mesmo, e composição farmacêutica

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: AS CLASSIFICACOES ANTERIORES ERAM: C07D 498/22 , C07D 413/14

Ipc: C07D 498/22 (2006.01), C07D 413/14 (2006.01), A61K

B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements